Abstract
Recombinant tissue plasminogen activator (t-PA) is the state of the art thrombolytic agent for myocardial infarction, but recombinant staphylokinase (STAR) has attracted recent interest. Laboratory data suggest that STAR, a protein secreted by some strains of Staphylococcus aureus, is considerably more fibrin-specific and therefore less likely to cause hemorrhagic complications. This open trial …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
